These increases were reversed in the EA group (Fig. 3E and G; 98.1 ± 6.62; 101.62 ± 10.3; 100.08 ± 4.39, respectively, p < 0.05) and the TRPV1−/− group (Fig. 3E and G; 99.3 ± 8.18; 102.98 ± 12.48; 100.84 ± 3.44, respectively, p < 0.05) compared with those in the MS group. This evidence concerns the gene TRPV1 and myeloid sarcoma.